Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$8.19 USD
+0.01 (0.12%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $8.20 +0.01 (0.12%) 5:26 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AMLX 8.19 +0.01(0.12%)
Will AMLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
Other News for AMLX
Amylyx Pharmaceuticals Q2 2025 Earnings Preview
Vanguard Group Inc's Strategic Acquisition in Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 | AMLX ...
BlackRock, Inc. Increases Stake in Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential